de Geus-Oei Lioe-Fee, van der Heijden Henricus F M, Corstens Frans H M, Oyen Wim J G
Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
Cancer. 2007 Oct 15;110(8):1654-64. doi: 10.1002/cncr.22979.
For several years, molecular imaging with (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) has become part of the standard of care in presurgical staging of patients with nonsmall-cell lung cancer (NSCLC), focusing on the detection of malignant lesions at early stages, early detection of recurrence, and metastatic spread. Currently, there is an increasing interest in the role of FDG-PET beyond staging, such as the evaluation of biological characteristics of the tumor and prediction of prognosis in the context of treatment stratification and the early assessment of tumor response to therapy. In this systematic review, the literature on the value of the evolving applications of FDG-PET as a marker for prediction (ie, therapy response monitoring) and prognosis in NSCLC is addressed, divided in sections on the predictive value of FDG-PET in locally advanced and advanced disease, the prognostic value of FDG-PET at diagnosis, after induction treatment, and in recurrent disease. Furthermore, the background and recommendations for the application of FDG-PET for these indications will be discussed.
数年来，使用（18）F - 氟脱氧葡萄糖正电子发射断层扫描（FDG - PET）进行分子成像已成为非小细胞肺癌（NSCLC）患者术前分期标准治疗的一部分，重点在于早期检测恶性病变、早期发现复发以及转移扩散情况。目前，人们对FDG - PET在分期之外的作用兴趣日增，比如评估肿瘤的生物学特性、在治疗分层背景下预测预后以及早期评估肿瘤对治疗的反应。在本系统评价中，探讨了关于FDG - PET作为NSCLC预测（即治疗反应监测）和预后标志物的不断演变的应用价值的文献，分为FDG - PET在局部晚期和晚期疾病中的预测价值、FDG - PET在诊断时、诱导治疗后以及复发性疾病中的预后价值等部分。此外，还将讨论FDG - PET用于这些指征的背景和建议。
